Ningbo Kunpeng Biological Technology

Kunpeng Bio is a clinical-stage biopharmaceutical company based in Ningbo, China, specializing in the development of high-end recombinant protein drugs and synthetic biology applications. The company's primary focus is on metabolic diseases, including diabetes and obesity, where it maintains a deep pipeline of insulin analogues and GLP-1 receptor agonists. Key programs include biosimilar versions of insulin glargine, lispro, and aspart, as well as a semaglutide candidate currently in Phase 3 clinical trials. Kunpeng Bio leverages proprietary high-efficiency expression platforms and large-scale GMP manufacturing capabilities to produce high-quality, cost-effective biologics. The company aims to address the growing global burden of chronic metabolic conditions through innovative manufacturing and rigorous clinical development.